Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Citriodiol for Childhood Impetigo
NCT01611909Phase 3
Key facts
- Status
- Unknown
- Start
- Jul 2012
- Primary completion
- Jan 2013
- Countries
- 1
- Sponsor
- Royal North Shore Hospital
- Modality
- Small Molecules
- Drugs
- Citrepel
- Conditions
- impetigo
01
Overview
Phase 3, randomised, double-blind trial of Citrepel in impetigo (3 arms), sponsored by Royal North Shore Hospital. Primary endpoint: Improvement in severity score of impetigo at 2 weeks. Status: unknown.
02
Design
3 arms- Study design
- RandomizedDouble-blind
2% PMDO
2% topical p-menthane-3,8-diol oil applied twice daily
5% PMDO
5% topical p-menthane-3,8-diol oil applied twice daily
Mupirocin
Topical Mupirocin applied twice daily
03
Who it enrols
Children aged 12 months to 12 years with dermatologist-confirmed impetigo, excluding those requiring systemic therapy or with other serious infections.
04
Endpoints
Primary
Improvement in severity score of impetigo
Beyond the preview
Go deeper on NCT01611909.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01611909.